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ABSTRACT
Introduction: The medications are the main therapeutic inputs in the treatment of type 
2 diabetes mellitus. When properly used, they allow disease control and reduction of 
morbidity and mortality, resulting in improvements in quality of life. Thus, the purpose 
of this article is to characterize the use of medications for type 2 diabetes mellitus 
with emphasis on gender differences.
Methods: A cross-sectional study performed in Family Health Units in Ribeirão Preto, 
São Paulo, Brazil, with 100 men and 100 women. Sociodemographic characteristics, 
clinical data, lifestyle and use of medications were the variables of interest.
Results: Mean number of diabetes medications referred by study participants was 
1.6 (SD = 0.7) for women and 1.5 (SD = 0.6) for men (p = 0.40). The use of metformin 
was mentioned by 70% of women and 65% of men, and adverse reactions were 
reported by 15% of women and 2% of men (p < 0.01). Medications were obtained 
mainly from public health system pharmacies in both genders.
Conclusions: Gender differences in the use of diabetes medications were found in 
reported adverse reactions, with more cases among women.
Keywords: Drug therapy; pharmacoepidemiology; pharmaceutical care; chronic 
disease; diabetes mellitus; family health strategy
Noncommunicable diseases (NCDs) are a global health problem, and 
diabetes mellitus (DM) is a major focus of concern1. In 2014, the estimated 
DM prevalence was 8.5% worldwide2. The scenario in Brazil is worrisome. 
The estimated DM prevalence in the country was 5.5% in 2006 and reached 
8.9% in 2016, which represents a 61.8% increase in the number of people 
diagnosed with DM in the last 10 years. The disease affects 9.9% of women 
and 7.8% of men3,4.
Type 2 DM accounts for 90-95% of the cases and is characterized by 
deficient insulin action and secretion and poor regulation of hepatic glucose 
production5,6. Type 2 DM associated with other NCDs is responsible for high 
proportions of mortality, costs with outpatient procedures, use of medications 
and hospital admissions7,8.
Prevention of complications related to type 2 DM is crucial. Disease control 
involves changes in lifestyle, including adoption of a diet plan and regular 
practice of physical exercise, as well as the use of medications5,6.
Medications play an important role in diabetes care. The current drugs 
to treat type 2 DM have different safety and effectiveness profiles. Besides, 
they may have effects on insulin deficiency or resistance or on intestinal 
glucose absorption5,6. There are also drugs that act on the reabsorption of 
glucose in the kidneys5,6. In evidence-based practice, antidiabetic drugs may 
be prescribed as monotherapy or combination therapy depending on the 
characteristics of the patient and the disease. It is known that medications, 
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when properly used, are able to control diabetes and 
reduce morbidity and mortality, resulting in improved 
quality of life9,10.
The literature shows that there are behavioral 
differences between men and women in diabetes care. 
Women are more alert to signs and symptoms and 
cherish self-care. Men usually seek health services in 
extreme situations or when they are unable to work8,9.
There are few studies on the use of medications to 
treat DM in the Family Health Strategy (FHS) focusing 
on the differences between men and women. Thus, 
the aim of the present study was to characterize the 
use of medications for type 2 DM with emphasis on 
gender differences.
METHODS
This is a cross-sectional study conducted at Family 
Health Units (FHUs) of the Western Sanitary District in 
Ribeirão Preto, São Paulo, Brazil, with adult patients 
diagnosed with type 2 DM and using medications to 
treat the disease. Patients with cognitive deficit or 
communication difficulty, bedridden patients, those 
who depended on caregivers, and those with history 
of surgeries or admissions in the 3 months prior to 
the interview were excluded.
The present study originates from the following 
master’s dissertation: “Adherence to type 2 diabetes 
mellitus pharmacotherapy at the Family Healthcare 
Strategy: a gender perspective”. The sample 
was calculated considering a 75% frequency of 
adherence to drug therapy, a margin of error of 
5%, and an alpha of 5%. The sample size was then 
estimated in 200 participants, which were divided 
proportionally to the number of patients with DM who 
were registered in six FHUs of the Western Sanitary 
District. The sample was stratified into four groups 
as follows: I – 50 female patients with type 2 DM 
aged 18-59 years; II – 50 female patients with type 
2 DM aged 60 years or more; III – 50 male patients 
with type 2 DM aged 18-59 years; and IV – 50 male 
patients with type 2 DM aged 60 years or more. 
A pilot test was performed in a non-registered FHU 
with 10 participants, who were not included in the 
final study sample.
This was a convenience sample, and the quota of 
each FHU was filled as patients sought the service. 
At the beginning of the interview, prescriptions, 
package inserts, blister packs and boxes of the 
medications used by each patient were requested. 
The instrument for data collection consisted of a 
questionnaire on sociodemographic data, health care, 
use of medications, and access to and use of health 
services. The Brief Medication Questionnaire was 
used to evaluate medications used, adherence and 
adverse reactions11. Data collection was conducted 
between November 2015 and April 2016.
In descriptive data analysis, frequencies and 
percentages were obtained for qualitative variables, 
and measures of dispersion for quantitative variables. 
The Pearson’s chi-square test was used to assess 
the association between variables of interest. 
The Student’s t-test was used to compare means. 
When necessary, the significance level was set at 
p < 0.05. Statistical analyses were performed using 
SAS version 9.2.
The research project was approved by the local 
Research Ethics Committee with protocol number 
47811515.9.0000.5414. All participants signed an 
informed consent form.
RESULTS
The study sample was characterized by low 
income and low level of education. Regarding 
socioeconomic status, 43% of women and 53% of 
men were categorized as classes D/E according to 
the Brazilian Economic Classification Criterion12. 
Regarding level of education, 77% of women and 
78% of men reported 8 or less years of schooling. 
The mean age was 63.9 years (SD = 13.7) in women 
and 59.5 years (SD = 13.9) in men. Most men and 
women reported being white (66% for both) and 
married (63% of women and 65% of men). Most men 
reported being employed/self-employed (57%) and 
most women reported being retired/pensioner (45%).
The mean number of medications used to treat 
DM was 1.6 (SD = 0.7) in women and 1.5 (SD = 0.6) 
in men (p = 0.40). Table 1 shows self-reported 
medications used to treat DM with a prevalence of 
metformin monotherapy in both genders. Metformin 
was the oral antidiabetic drug (OAD) most mentioned 
as a potential cause of adverse reactions, reported by 
15% of women and 2% of men (p < 0.01) (Table 2). 
Diarrhea was reported as the main symptom by 13% 
of women and 1% of men (Table 3).
Medications were mostly or partially obtained from 
public health system pharmacies by 65% of women 
Table 1: Self-reported medications for the treatment of 
type 2 diabetes mellitus in Family Health Units according 
to gender. Ribeirão Preto, SP, 2016.
Medications Womenn = 100
Men
n = 100
Metformin alone 35 33
Sulfonylurea alone 12 14
Insulin alone 10 16
Metformin + sulfonylurea 22 18
Oral antidiabetic drug + insulin 17 17
Others 4 2
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and 71% of men. The Brazilian Popular Pharmacy 
Program (BPPP), a government program of co-payment 
in the private system, was used by 29% of women 
and 26% of men to obtain their medications (Table 4).
DISCUSSION
This study included FHU patients who used at 
least one medication to treat type 2 DM. The results 
of the 2013 Brazilian National Health Survey showed 
that 80.2% of the participants who reported having 
diabetes used medications, with higher proportion 
in the South-East region and lower proportion in the 
North region. In addition, no significant differences 
were found between genders according to the point 
estimates for the Brazilian regions11.
In the present study, the mean number of 
medications used to treat type 2 DM was higher 
among women. However, there were no statistically 
significant differences in the comparison of means 
between genders. This finding differs from a study 
with patients with type 2 DM in a Primary Health 
Care Unit in Ijuí, Rio Grande do Sul, in which the 
mean number of medications was 2.2 (SD = 1.0) in 
women and 2.7 (SD = 0.8) in men13.
Metformin was the most mentioned medication 
by both genders. Current guidelines of the Brazilian 
Diabetes Association and the American Diabetes 
Association are consistent in terms of metformin 
prescription, associated with changes in lifestyle, 
for patients recently diagnosed with type 2 DM5,6. 
However, monotherapy may not be enough to obtain 
glycemic control, and it is often necessary to combine 
other OADs according to disease progression10.
The literature suggests caution in the prolonged 
use of metformin, which may cause vitamin B12 
deficiency. One of the likely causes of diabetic 
neuropathy is associated with this type of deficiency14. 
Also, although metformin has low potential for drug 
interaction, a careful evaluation should be performed 
when using it concomitantly with medications that 
cause harm to the renal function15.
A pharmacotherapy study of type 2 DM conducted 
in a FHU in João Pessoa, Paraíba, found that 96.9% 
of men (who represented 50% of the sample) used 
OAD and the other ones used insulin alone. Of the 
participants who used OAD, 38.7% used metformin 
combined with glibenclamide, 32.3% metformin 
alone, 19.4% glibenclamide alone, 6.5% metformin 
combined with glimepiride, and 3.2% glimepiride 
alone. In addition, 12.5% of the study participants 
reported adverse reaction and attributed it to the 
use of OAD. The listed symptoms were stomach 
pain/discomfort or headache, and all patients who 
reported these used metformin. The authors did not 
specify the proportion of adverse reaction according 
to gender16.
Potential adverse reactions to metformin were reported 
by both genders in the present study, predominantly 
in women. The literature shows that this OAD may 
cause abdominal discomfort, diarrhea and headache. 
It also shows that extended-release formulations of 
this medication may cause less adverse events5,6. 
A randomized clinical trial conducted in 27 health 
centers in the United States with 2,155 patients 
with type 2 DM divided into 2 groups – metformin 
and placebo – showed that women in the metformin 
group reported more adverse reactions (p = 0.002)17.
In the present study, the main source of medications 
were the public health system pharmacies, followed 
by the BPPP, in both genders. Data from the 2014 
Brazilian National Survey on Access, Utilization and 
Promotion of Rational Use of Medications showed that 
78.6% (95% CI: 75.6-81.3) of diabetes medications 
were obtained free of charge18.
The 2013 National Health Survey showed that 
57.4% of patients with DM used at least one medication 
Table 2: Self-reported medications that caused adverse 
reactions according to gender. Ribeirão Preto, SP, 2016.








Saxagliptin + metformin 1 0
Dapagliflozin 1 0
Table 3: Adverse drug reactions reported by study participants 
according to gender. Ribeirão Preto, SP, 2016.





Taste of blood in the mouth 1 1
Others 3 1
Table 4: Sources of medication acquisition for the treatment 
of type 2 diabetes mellitus reported by the study participants 
in Family Health Units according to gender. Ribeirão Preto, 
SP, 2016.
Sources of medication acquisition Womenn = 100
Men
n = 100
Public health system pharmacy 55 60
Brazilian Popular Pharmacy Program 29 26
Commercial pharmacy 4 3
Public health system pharmacy + 
Brazilian Popular Pharmacy Program
10 11
Public health system pharmacy + 
Commercial pharmacy
2 0
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provided by the BPPP. Higher proportions of acquisition 
through BPPP were found in black patients (69.4%) 
and in patients with lower level of education (≤ 8 years 
of schooling) (63.9%). Regarding gender, even without 
statistically significant differences, women from most 
regions tended to obtain more diabetes medications 
from the BPPP than men19.
The present study contributed to expand the 
knowledge on type 2 DM pharmacotherapy, particularly 
in the FHS. Data presented here provide reflections 
to health care and chronic disease management. 
However, some limitations should be considered. 
Information on the continuous use of type 2 DM 
medications was collected. Conversely, information 
on home use of medications to treat other diseases, 
as well as on use of medications to treat acute 
conditions, phytotherapeutic drugs, homeopathic 
drugs and self-medication, was not collected. Also, 
pharmacotherapy quality was not assessed. Memory 
bias when describing medications used and adverse 
reactions is another limitation of this study. However, 
prescribed medications were consistent with current 
guidelines for diabetes treatment5,6.
The present study showed a prevalence of 
monotherapy for the treatment of type 2 DM in both 
genders. Metformin was the most mentioned OAD 
and was associated with potential adverse reactions in 
women more often. Most medications were obtained 
from public health system pharmacies or through the 
BPPP. It is worth highlighting the importance of the 
implementation of actions to promote the rational 
use of medications considering pharmacotherapy 
characteristics of men and women with type 2 DM 
in the FHS.
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